Multiple Myeloma

Survival Benefit Observed Following Treatment With Belantamab Mafodotin for Relapsed/Refractory Myeloma

The final analysis from the phase 2 DREAMM-2 study found continued efficacy in patients who had relapsed/refractory multiple myeloma.

$A triple-class exposed population of patients diagnosed with relapsed or refractory multiple myeloma experienced progression-free survival benefit following treatment with belantamab mafodotin with pomalidomide and dexamethasone.$

Nichole Tucker

Improvement of HRQOL Observed With Daratumumab-Quadruplet in Transplant Eligible, Newly Diagnosed Multiple Myeloma

A triple-class exposed population of patients diagnosed with relapsed or refractory multiple myeloma experienced progression-free survival benefit following treatment with belantamab mafodotin with pomalidomide and dexamethasone.

Lindsay Fischer

Promising Efficacy Profile Observed With Mezigdomide Plus Dexamethasone in Pretreated Multiple Myeloma

A quadruplet regimen with daratumumab as its base was found to improve health related quality of life in patients with transplant-eligible, newly diagnosed multiple myeloma.

Wayne Kuznar

IV, Subcutaneous Forimtamig Induces Effective, High Response Rates in Relapsed/Refractory Multiple Myeloma

Efficacy and safety findings were positive in the phase 1/2 CC-92480-MM-001 trial when mezigdomide was added to dexamethasone in patients with heavily pretreated multiple myeloma.

$The findings, according to the lead study author, demonstrate that treatment with forimtamig delivered intravenously or subcutaneously may elicit long-term responses in patients with relapsed or refractory multiple myeloma.$

Ryan McDonald

Elranatamab Produces Efficacy Response in Penta-or Triple-Class Refractory Multiple Myeloma

The findings, according to the lead study author, demonstrate that treatment with forimtamig delivered intravenously or subcutaneously may elicit long-term responses in patients with relapsed or refractory multiple myeloma.

$Elranatamab Produces Efficacy Response in Penta-or Triple-Class Refractory Multiple Myeloma$

Silas Inman

Teclistamab Combination Therapy Produces Promising Safety Profile in Relapsed/Refractory Multiple Myeloma

Patients with penta-or triple-class refractory multiple myeloma who have not received prior B-cell maturation antigen therapy saw an improved objective response rate when elranatamab was given.

$Teclistamab Combination Therapy Produces Promising Safety Profile in Relapsed/Refractory Multiple Myeloma$

Talquetamab Continues to Elicit High Treatment Responses in a Heavily Pre-treated Multiple Myeloma Population

Findings from the phase 1b MajesTEC-2 trial indicated that teclistamab in combination with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.

Hayley Virgil

Bispecifics in Development for the Treatment of R/R MM

The use of two separate recommended phase 2 doses of talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma, according to updated trial findings presented at 2022 American Society of Hematology Annual Meeting.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Practical Factors in Selecting Therapy for Relapsed/Refractory MM

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Patient Case 3: A 65-Year-Old Woman With Relapsed Multiple Myeloma

Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Treatment Options for Patients with Relapsed Multiple Myeloma

After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Recap: A Review of the Treatment Landscape in Multiple Myeloma

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina Patel, MD

December 6th 2022

A panel of experts discusses the treatment approaches to three clinical cases of multiple myeloma in the context of data presented at recent meetings and reviews how it can be applied to daily clinical practice.

Defining Frail Patients in Multiple Myeloma

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Transplant-Ineligible NDMM: Optimizing Selection and Duration of Therapy

Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.

Sundar Jagannath, MD;Adriana C. Rossi, MD;Shambavi Richard, MD;Joshua Richter, MD

Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMD

Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.

Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.

Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple Myeloma

November 30th 2022

Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.

$Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.$

Unmet Needs and Future Directions in Multiple Myeloma Treatment

November 28th 2022

Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.

The panel sits behind a desk, smiling at the camera.

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina Patel, MD

CAR T-Cell Therapy in Multiple Myeloma Treatment

The panel closes their discussions by highlighting current unmet needs in multiple myeloma treatment and what excites them on the horizon.

Rafael Fonseca, MD;Amrita Y. Krishnan, MD;Caitlin Costello, MD;Krina Patel, MD

Data Updates in Transplant Ineligible NDMM

Dr Patel continues the conversation of novel treatments with an examination of CAR T-cell therapies in multiple myeloma.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM

Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

Closing out their module on transplant-ineligible NDMM management, expert panelists consider best practices regarding duration of therapy and adjustments to drug regimens.

Peter Voorhees, MD;Cristina Gasparetto, MD;Cindy Varga, MD;Sascha Tuchman, MD

Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM

Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.

Alfred Garfall, MD;Edward A. Stadtmauer, MD;Dan Vogl, MD;Sandara Susanibar-Adaniya, MD

‘Virtually All Patients’ with Newly Diagnosed Transplant-Ineligible Myeloma Achieve Response With Addition of Daratumumab to Lenalidomide-Dexamethasone Combo

Comprehensive discussion on the array of treatment regimens available for patients with transplant-ineligible NDMM and how best to sequence therapy.

According to an expert, more than 90% of patients with newly diagnosed transplant-ineligible multiple myeloma treated with daratumumab plus lenalidomide and dexamethasone will achieve some type of response.